Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis
Conditions
Interventions
Zabedosertib (BAY1834845)
Placebo to zabedosertib (BAY1834845)
Locations
22
United States
NorthShore University HealthSystem | Skokie Hospital - Dermatology Department
Skokie, Illinois, United States
Beth Israel Deaconess Medical Center - Dermatology
Boston, Massachusetts, United States
University of Cincinnati College of Medicine - Dermatology
Cincinnati, Ohio, United States
Arlington Research Center, Inc. | Arlington, TX
Arlington, Texas, United States
Dermamedica s.r.o.
Náchod, Hradec Králové Region, Czechia
Clintrial s.r.o.
Prague, Czechia
Start Date
December 21, 2022
Primary Completion Date
January 3, 2024
Completion Date
January 31, 2024
Last Updated
February 18, 2025
NCT07298395
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions